6467 Stock Overview
A pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Taho Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$49.50 |
| 52 Week High | NT$67.80 |
| 52 Week Low | NT$32.25 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6467 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | n/a | 2.1% | -0.7% |
| 1Y | n/a | 1.5% | 28.8% |
Return vs Industry: Insufficient data to determine how 6467 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6467 performed against the TW Market.
Price Volatility
| 6467 volatility | |
|---|---|
| 6467 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6467's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 6467's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Howard Lee | www.tahopharma.com |
Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. The company’s portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which is in phase 1 clinical trial for opioid overdose; TAH9922 atomoxetine oral liquid, which is in phase 1 clinical trial; and TAH9901 methylphenidate patch, which is in phase 1 clinical trial for the treatment of deficit and hyperactivity disorder. The company was founded in 2010 and is based in Taipei, Taiwan.
Taho Pharmaceuticals Ltd. Fundamentals Summary
| 6467 fundamental statistics | |
|---|---|
| Market cap | NT$2.54b |
| Earnings (TTM) | -NT$66.30m |
| Revenue (TTM) | NT$6.36m |
0.0x
P/S Ratio0.0x
P/E RatioIs 6467 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6467 income statement (TTM) | |
|---|---|
| Revenue | NT$6.36m |
| Cost of Revenue | NT$1.30m |
| Gross Profit | NT$5.06m |
| Other Expenses | NT$71.35m |
| Earnings | -NT$66.30m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6467 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:10 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taho Pharmaceuticals Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|